KR960021033A - Pharmaceutical composition containing bamboo salt and antacid - Google Patents

Pharmaceutical composition containing bamboo salt and antacid Download PDF

Info

Publication number
KR960021033A
KR960021033A KR1019940039918A KR19940039918A KR960021033A KR 960021033 A KR960021033 A KR 960021033A KR 1019940039918 A KR1019940039918 A KR 1019940039918A KR 19940039918 A KR19940039918 A KR 19940039918A KR 960021033 A KR960021033 A KR 960021033A
Authority
KR
South Korea
Prior art keywords
antacid
composition according
magnesium
calcium
pharmaceutical composition
Prior art date
Application number
KR1019940039918A
Other languages
Korean (ko)
Inventor
이승준
장석윤
하재몽
Original Assignee
성재갑
주식회사 Lg 화학
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 성재갑, 주식회사 Lg 화학 filed Critical 성재갑
Priority to KR1019940039918A priority Critical patent/KR960021033A/en
Publication of KR960021033A publication Critical patent/KR960021033A/en

Links

Abstract

본 발명은 죽염과 제산제를 함유하는 소화기계용 의약조성물에 관한 것이다. 본 발명에서는 죽염의 항염증 작용과 제산제의 산중화작용을 이용하여 위궤양의 염증도 치료하고 제산작용에 의한 통증을 신속히 완화시키는 상승효과가 있다.The present invention relates to a pharmaceutical composition for digestive system containing bamboo salt and antacid. In the present invention, there is a synergistic effect of treating inflammation of the gastric ulcer by using the anti-inflammatory action of the bamboo salt and the acid neutralizing action of the antacid and quickly alleviating the pain caused by the antacid.

Description

죽염과 제산제를 함유하는 약제학적 조성물Pharmaceutical composition containing bamboo salt and antacid

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음As this is a public information case, the full text was not included.

Claims (15)

5∼67중량%의 죽염과 5∼27중량%의 제산제 및 7∼90중량%의 기타성분을 함유하는 소화기계용 의약조성물.A pharmaceutical composition for the digestive system containing 5 to 67% by weight of bamboo salt, 5 to 27% by weight of antacid and 7 to 90% by weight of other components. 제1항에 있어서, 1회 복용량에 제산제 함유량이 150∼600mg 인 조성물.The composition according to claim 1, wherein the antacid content is 150 to 600 mg in one dose. 제1항에 있어서, 1회 복용량에 죽염 함유량이 450∼1200mg 인 조성물.The composition according to claim 1, wherein the bamboo salt content is 450 to 1200 mg in a single dose. 제1항 내지 제4항중 어느 하나에 있어서, 제산제가 알마게이트, 히드로탈사이트, 마갈드레이트 또는 기타 제산마그네슘 화합물, 제산알루미늄 화합물, 제산칼슘 화합물 중의 하나 또는 둘이상의 조합임을 특징으로 하는 조성물.The composition according to any one of claims 1 to 4, wherein the antacid is one or a combination of almagate, hydrotalcite, magaldrate or other magnesium antacid compound, aluminum antacid compound, calcium antacid compound. 제4항에 있어서, 제산마그네슘 화합물이 마그네슘 카보네이트, 마그네슘 카보네이트 히드록사이드, 마그네슘 수산화물, 마그네슘 산화물, 마그네슘 규조산화물 중의 하나 또는 둘 이상의 조합임을 특징으로 하는 조성물.The composition of claim 4 wherein the magnesium antacid compound is one or a combination of two or more of magnesium carbonate, magnesium carbonate hydroxide, magnesium hydroxide, magnesium oxide, magnesium diatom oxide. 제4항에 있어서, 제산알루미늄 화합물이 수산화 알루미늄, 알루미늄 마그네슘 히드록사이드, 건조 알루미늄 히드록사이드 겔중의 하나 또는 둘 이상의 조합임을 특징으로 하는 조성물.The composition of claim 4 wherein the aluminum antacid compound is one or a combination of two or more of aluminum hydroxide, aluminum magnesium hydroxide, and dry aluminum hydroxide gel. 제4항에 있어서, 제산칼슘 화합물이 산화칼슘 칼슘카보네이트, 칼슘 수산화물 중의 하나 또는 둘 이상의 조합임을 특징으로 하는 조성물.The composition according to claim 4, wherein the calcium antacid compound is one or a combination of two or more of calcium oxide calcium carbonate and calcium hydroxide. 제1항에 있어서, 기타 성분이 희석제, 수용성 또는 수불용성 붕해제, 감미제, 풍미제, 결합제 및 약학적으로 허용가능한 부형제, 담체 중의 하나 또는 둘 이상의 조합인 조성물.The composition of claim 1 wherein the other component is one or a combination of diluents, water soluble or water insoluble disintegrants, sweeteners, flavors, binders and pharmaceutically acceptable excipients, carriers. 제8항에 있어서, 희석제가 인산칼슘, 황상칼슘, 만니톨, 셀룰로오스, 스타치, 기타 당종류나 당알콜중의 하나 또는 둘 이상의 조합인 조성물.The composition of claim 8 wherein the diluent is one or more of calcium phosphate, calcium sulfate, mannitol, cellulose, starch, other sugars, or sugar alcohols. 제1항에 있어서, 위산분비억제제를 추가로 함유하는 것을 특징으로 하는 조성물.The composition according to claim 1, further comprising a gastric acid secretion inhibitor. 제10항에 있어서, 위산분비억제제가 시메티딘, 오메프라졸, 라나티딘인 것을 특징으로 하는 조성물.The composition of claim 10, wherein the gastric acid secretion inhibitor is cimetidine, omeprazole, lanatidine. 제1항 내지 제3항중 어느 하나에 있어서, 정제형, 과립형, 세립형, 캡슐형의 제형을 가진 조성물.The composition according to any one of claims 1 to 3, which has a tablet, granular, fine granular, capsule form formulation. 제1항에 있어서, 제형이 현탁액제 또는 겔제인 의약조성물.The pharmaceutical composition according to claim 1, wherein the formulation is a suspension or a gel. 제13항에 있어서, 1회 복용량내에 제산제가 150∼500mg 함유된 의약조성물.The pharmaceutical composition according to claim 13, wherein the pharmaceutical composition contains 150 to 500 mg of an antacid in a single dose. 제13 또는 제14항에 있어서, 1회 복용량내에 죽염이 150∼200mg 함유된 의약조성물.The pharmaceutical composition according to claim 13 or 14, which contains 150 to 200 mg of bamboo salt in a single dose. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019940039918A 1994-12-30 1994-12-30 Pharmaceutical composition containing bamboo salt and antacid KR960021033A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019940039918A KR960021033A (en) 1994-12-30 1994-12-30 Pharmaceutical composition containing bamboo salt and antacid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019940039918A KR960021033A (en) 1994-12-30 1994-12-30 Pharmaceutical composition containing bamboo salt and antacid

Publications (1)

Publication Number Publication Date
KR960021033A true KR960021033A (en) 1996-07-18

Family

ID=66647966

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940039918A KR960021033A (en) 1994-12-30 1994-12-30 Pharmaceutical composition containing bamboo salt and antacid

Country Status (1)

Country Link
KR (1) KR960021033A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012165736A1 (en) * 2011-05-27 2012-12-06 목포대학교산학협력단 Remedy for gastritis and gastric ulcer
KR101401142B1 (en) * 2011-05-27 2014-05-30 목포대학교산학협력단 using method of red-salt as effective material for gastritis and stomach ulcer prevention

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR890004712A (en) * 1987-09-10 1989-05-09 김윤세 Nuclear arsenic-containing bamboo salt and its manufacturing method
KR950028773A (en) * 1994-04-29 1995-11-22 염응수 Garlic sugar-coated preparation containing bamboo salt

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR890004712A (en) * 1987-09-10 1989-05-09 김윤세 Nuclear arsenic-containing bamboo salt and its manufacturing method
KR950028773A (en) * 1994-04-29 1995-11-22 염응수 Garlic sugar-coated preparation containing bamboo salt

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012165736A1 (en) * 2011-05-27 2012-12-06 목포대학교산학협력단 Remedy for gastritis and gastric ulcer
KR101401142B1 (en) * 2011-05-27 2014-05-30 목포대학교산학협력단 using method of red-salt as effective material for gastritis and stomach ulcer prevention
US9895409B2 (en) 2011-05-27 2018-02-20 Mokpo National University Industry-Academia Cooperation Group Remedy for gastritis and gastric ulcer

Similar Documents

Publication Publication Date Title
US4866046A (en) Low-dosage sublingual aspirin
CA2020018A1 (en) Method and composition for treating the migraine complex
US4252790A (en) Method for treating gastric ulcer-prone patients
KR0149029B1 (en) Anti-diarrheal composition
ES2261796T3 (en) COMPOSITION FOR THE TREATMENT OF CHRONIC VENOUS INSUFFICIENCIES THAT INCLUDES A RED VID LEAF EXTRACT.
ATE243030T1 (en) ORAL PREPARATION FOR PROPHYLACTIC/THERAPEUTIC TREATMENT OF HELICOBACTOR SP. INFECTIONS
Salmon et al. Evaluation of colloidal bismuth (De-Nol) in the treatment of duodenal ulcer employing endoscopic selection and follow up
Ravdin Hypoproteinemia and its relation to surgical problems
CZ382799A3 (en) Use of zinc hyaluronate against peptic ulcers
CA2038744A1 (en) Pharmaceutical composition containing slightly water-soluble drug
RU2126249C1 (en) Pharmaceutical composition for oral administration for treatment of patients with pathology of gastroenteric tract upper regions
US5397573A (en) Laxative compositions
CN111836629A (en) Pharmaceutical composition
KR960021033A (en) Pharmaceutical composition containing bamboo salt and antacid
US7795239B2 (en) Saccharide compositions and method of use
Salim Use of scavenging oxygen‐derived free radicals to protect the rat against aspirin‐and ethanol‐induced erosive gastritis
US11357813B2 (en) Composition comprising tannins
CA2250221A1 (en) Pharmaceutical compositions containing alendronate and an agent promoting gastric emptying
EP0814773B1 (en) Pectin liquid pharmaceutical compositions
US4216207A (en) Method and composition for treatment of gastro-duodenal ulcers
US3369968A (en) Composition and method of absorbing gas in teh intestine
GB2174004A (en) Effervescent tablets
Moshal et al. Trimipramine in the treatment of active duodenal ulceration
US5661137A (en) Antacid pharmaceutical composition in the form of a suspension based on sucralfate gel
CA2184361C (en) Solid dose forms containing bismuth

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application